Radiology’s Commodity Trap is Just the Tip of the Spear in a Broken System

Radiology isn’t a blood test. That’s the refreshingly clear message from Amy Cosler, Chief Growth & Partnerships Officer at Covera Health, in a recent CB Insights interview. She argues that imaging has been treated like a commodity for too long—you can go anywhere and get the same answer—when in reality, it behaves nothing like one. It’s a view that will resonate with anyone who’s ever faced a missed diagnosis or a confusing radiologist’s report. But here’s the thing: the commoditization mindset doesn’t stop at the MRI machine. It’s a systemic undercurrent that drags down the entire healthcare workforce, and the fallout is both measurable and deeply alarming.

Cosler’s point hits hard because it aligns with a pattern I see again and again in our data across the entire Healthcare industry. The thinking goes: “A scan is a scan,” or “a nurse is a nurse.” That false equivalence leads to chronic under-resourcing, and the consequences are brutal. For example, PainSignal reveals a problem where nurses in long-term care facilities are pressured by corporate policy to delay sending critically declining residents to the hospital. The severity? A maximum 5 out of 5. That’s not just a staffing issue—it’s a direct result of a system that sees care as a line item rather than a critical, specialized human endeavor.

What’s more, the damage isn’t limited to patients. The workforce itself is buckling. We track a 5/5 severity problem where a nurse with just two years of experience feels severely burned out and lacks confidence due to chronic understaffing. Another shows nurses in acute psychiatric units facing patently unsafe patient-to-nurse ratios. These aren’t one-off anecdotes; they’re signals pointing to a deep-rooted undervaluation of clinical expertise that mirrors the radiology commoditization Cosler describes. When you treat skilled professionals as interchangeable parts, burnout skyrockets, and safety plummets.

For indie hackers and agency devs, these twin crises—quality gaps and workforce strain—aren’t just problems to mourn; they’re blueprints for high-impact solutions. The data backs this up. Among the 455 app ideas logged in Healthcare, we’re seeing a surge in concepts that directly tackle both diagnostic accuracy and clinician support. Take DoseGuard Infusion, an AI-powered infusion management system with an opportunity score of 67 out of 100. Or VitalLink Alert, a real-time vital sign monitoring tool. These aren’t just cool tech; they’re responses to the exact commoditization failures that lead to missed alarms and burned-out nurses. They integrate quality assurance with workflow automation, which is precisely the combo that Covera’s thesis implies but doesn’t fully explore.

Investors should pay close attention to this integrated approach. The market is hungry for platforms that tie quality metrics to operational resilience. We’re tracking 757 problems in Healthcare with an average severity of 4.1 out of 5—that’s a sea of pain that won’t be solved by point solutions alone. The next big health-tech winner might look less like a standalone radiology QA tool and more like an ecosystem that ensures a nurse never has to decide between following a dangerous protocol and losing their job, while simultaneously flagging imaging discrepancies in real time.

What makes this moment interesting is that the commoditization mindset is finally cracking under the weight of its own consequences. Cosler’s interview is a signpost. But for those of us who dig into the daily reality of healthcare workers, the conversation needs to broaden—and fast. The opportunities are hiding in plain sight: build for the clinician who’s been stripped of their judgment, for the patient who’s been reduced to a protocol, for the system that forgot that expertise matters. That’s where the value is. That’s where the next Covera Health—but for nursing, for pharmacy, for mental health—will come from.

So yes, imaging isn’t a commodity. Neither is a nurse’s assessment, a pharmacist’s review, or a therapist’s session. The data says so. And for savvy builders and investors, that realization isn’t just a philosophy—it’s a market map.